2 prosjekter

PES-HORISONT-EU-PES Horisont Europa

Clinical development of curcuma-derived turmerones as a breakthrough therapy for patients with rare childhood epilepsies.

Theracule is developing a new first-in-class therapeutic for the treatment of rare childhood epilepsies. TCA-001 is a botanical drug with a novel mechanism of action, and with preclinical safety and anti-seizure efficacy in animal models that show its potential to be a breakthrough therapy for tr...

Tildelt: kr 74 999

Prosjektperiode: 2021-2022

Sted: Oslo

PES2020-Prosj.etabl.støtte H2020

Development of a novel medication for treatment of drug refractory childhood epilepsy

Theracule is developing a new turmeric oil-derived therapeutic for the treatment of drug-refractory childhood epilepsy. The main compound, TCA-01, is sourced from the turmeric root, and designed to provide an alternative for patients currently refractory to classical epilepsy medications. TCA-0...

Tildelt: kr 99 999

Prosjektperiode: 2020-2021

Sted: Oslo